U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results